Funding

Publications (since 2010)

  1. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens. Zhao J, Cochrane CS, Najeeb J, Gooden D, Sciandra C, Fan P, Lemaitre N, Newns K, Nicholas RA, Guan Z, Thaden JT, Fowler VG Jr, Spasojevic I, Sebbane F, Toone EJ, Duncan C, Gammans R, Zhou P. Sci Transl Med. 2023 Aug 9;15(708):eadf5668. doi: 10.1126/scitranslmed.adf5668.

  2. A Widefield Light Microscopy-Based Approach Provides Further Insights into the Colonization of the Flea Proventriculus by Yersinia pestis. Dewitte A, Werkmeister E, Pierre F, Sebbane F, Bontemps-Gallo S. Appl Environ Microbiol. 2023 Apr 26;89(4):e0209122. doi: 10.1128/aem.02091-22.

  3. No evidence for persistent natural plague reservoirs in historical and modern Europe. Stenseth NC, Tao Y, Zhang C, Bramanti B, Büntgen U, Cong X, Cui Y, Zhou H, Dawson LA, Mooney SJ, Li D, Fell HG, Cohn S, Sebbane F, Slavin P, Liang W, Tong H, Yang R, Xu L. Proc Natl Acad Sci U S A. 2022 Dec 20;119(51):e2209816119. doi: 10.1073/pnas.2209816119.

  4. Emergence and spread of ancestral Yersinia pestis in Late-Neolithic and Bronze-Age Eurasia, ca. 5,000 to 1,500 y B.P. Slavin P, Sebbane F. Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2204044119. doi: 10.1073/pnas.2204044119.

  5. Interplay between Yersinia pestis and its flea vector in lipoate metabolism. Bouvenot T, Dewitte A, Bennaceur N, Pradel E, Pierre F, Bontemps-Gallo S, Sebbane F. ISME J. 2021 Apr;15(4):1136-1149. doi: 10.1038/s41396-020-00839-0.

  6. A refined model of how Yersinia pestis produces a transmissible infection in its flea vector. Dewitte A, Bouvenot T, Pierre F, Ricard I, Pradel E, Barois N, Hujeux A, Bontemps-Gallo S, Sebbane F. PLoS Pathog. 2020 Apr 15;16(4):e1008440. doi: 10.1371/journal.ppat.1008440.

  7. Nutrient depletion may trigger the Yersinia pestis OmpR-EnvZ regulatory system to promote flea-borne plague transmission. Bontemps-Gallo S, Fernandez M, Dewitte A, Raphaël E, Gherardini FC, Pradel E., Koch L, Biot F, Reboul A, Sebbane F. Mol Microbiol. 2019 Nov;112(5):1471-1482. doi: 10.1111/mmi.14372.

  8. Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model. Daniel C, Dewitte A, Poiret S, Marceau M, Simonet M, Marceau L, Descombes G, Boutillier D, Bennaceur N, Bontemps-Gallo S, Lemaître N, Sebbane F. Front Immunol. 2019 Aug 2;10:1830. doi: 10.3389/fimmu.2019.01830.

  9. To block or not to block: The adaptive manipulation of plague transmission. Gandon S, Heitzmann L, Sebbane F. Evol Lett. 2019 Mar 27;3(2):152-161. doi: 10.1002/evl3.111.

  10. Transcriptomic studies and assessment of Yersinia pestis reference genes in various conditions. Koch L, Poyot T, Schnetterle M, Guillier S, Soulé E, Nolent F, Gorgé O, Neulat-Ripoll F, Valade E, Sebbane F, Biot F. Sci Rep. 2019 Feb 21;9(1):2501. doi: 10.1038/s41598-019-39072-x.

  11. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC. Lemaître N, Liang X, Najeeb J, Lee CJ, Titecat M, Leteurtre E, Simonet M, Toone EJ, Zhou P, Sebbane F. mBio. 2017 Jul 25;8(4):e00674-17. doi: 10.1128/mBio.00674-17.

  12. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis. Daniel C, Titecat M, Poiret S, Cayet D, Boutillier D, Simonet M, Sirard JC, Lemaître N, Sebbane F. Vaccine. 2016 Nov 11;34(47):5762-5767. doi: 10.1016/j.vaccine.2016.09.060.

  13. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. Titecat M, Liang X, Lee CJ, Charlet A, Hocquet D, Lambert T, Pagès JM, Courcol R, Sebbane F, Toone EJ, Zhou P, Lemaitre N. J Antimicrob Chemother. 2016 Oct;71(10):2874-82. doi: 10.1093/jac/dkw210.

  14. Evaluation of the Role of the opgGH Operon in Yersinia pseudotuberculosis and Its Deletion during the Emergence of Yersinia pestis. Quintard K, Dewitte A, Reboul A, Madec E, Bontemps-Gallo S, Dondeyne J, Marceau M, Simonet M, Lacroix JM, Sebbane F. Infect Immun. 2015 Sep;83(9):3638-47. doi: 10.1128/IAI.00482-15. Epub 2015 Jul 6. PMID: 26150539

  15. Superantigenic Yersinia pseudotuberculosis induces the expression of granzymes and perforin by CD4+ T cells. Goubard A, Loïez C, Abe J, Fichel C, Herwegh S, Faveeuw C, Porte R, Cayet D, Sebbane F, Penet S, Foligné B, Desreumaux P, Saito H, Sirard JC, Simonet M, Carnoy C. Infect Immun. 2015 May;83(5):2053-64. doi: 10.1128/IAI.02339-14.

  16. Functional and structural analysis of HicA3-HicB3, a novel toxin-antitoxin system of Yersinia pestis. Bibi-Triki S, Li de la Sierra-Gallay I, Lazar N, Leroy A, Van Tilbeurgh H, Sebbane F, Pradel E. J Bacteriol. 2014 Nov;196(21):3712-23. doi: 10.1128/JB.01932-14.

  17. Yersinia pestis requires the 2-component regulatory system OmpR-EnvZ to resist innate immunity during the early and late stages of plague. Reboul A, Lemaître N, Titecat M, Merchez M, Deloison G, Ricard I, Pradel E, Marceau M, Sebbane F. J Infect Dis. 2014 Nov 1;210(9):1367-75. doi: 10.1093/infdis/jiu274.

  18. New insights into how Yersinia pestis adapts to its mammalian host during bubonic plague. Pradel E, Lemaître N, Merchez M, Ricard I, Reboul A, Dewitte A, Sebbane F. PLoS Pathog. 2014 Mar 27;10(3):e1004029. doi: 10.1371/journal.ppat.1004029. 

  19. Proposed reclassification of Pasteurella lymphangitidis Sneath & Stevens 1990 as Yersinia pseudotuberculosis. Gaillot O, Lemenand O, Marceau M, Simonet M. Int J Syst Evol Microbiol. 2013 Oct;63(Pt 10):3927-3929. doi: 10.1099/ijs.0.051524-0.

  20. Inheritance of the lysozyme inhibitor Ivy was an important evolutionary step by Yersinia pestis to avoid the host innate immune response. Derbise A, Pierre F, Merchez M, Pradel E, Laouami S, Ricard I, Sirard JC, Fritz J, Lemaître N, Akinbi H, Boneca IG, Sebbane F. J Infect Dis. 2013 May 15;207(10):1535-43. doi: 10.1093/infdis/jit057.

  21. Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague. Lemaître N, Ricard I, Pradel E, Foligné B, Courcol R, Simonet M, Sebbane F. PLoS One. 2012;7(12):e52503. doi: 10.1371/journal.pone.0052503. Epub 2012 Dec 20.

  22. In silico comparison of Yersinia pestis and Yersinia pseudotuberculosis transcriptomes reveals a higher expression level of crucial virulence determinants in the plague bacillus. Chauvaux S, Dillies MA, Marceau M, Rosso ML, Rousseau S, Moszer I, Simonet M, Carniel E. Int J Med Microbiol. 2011 Feb;301(2):105-16. doi: 10.1016/j.ijmm.2010.08.013. Epub 2010 Oct 15.

  23. Role of the Yersinia pestis yersiniabactin iron acquisition system in the incidence of flea-borne plague. Sebbane F, Jarrett C, Gardner D, Long D, Hinnebusch BJ. PLoS One. 2010 Dec 17;5(12):e14379. doi: 10.1371/journal.pone.0014379.

  24. Autophagosomes can support Yersinia pseudotuberculosis replication in macrophages. Moreau K, Lacas-Gervais S, Fujita N, Sebbane F, Yoshimori T, Simonet M, Lafont F. Cell Microbiol. 2010 Aug;12(8):1108-23. doi: 10.1111/j.1462-5822.2010.01456.x.

  25. Body lice, yersinia pestis orientalis, and black death. Ayyadurai S, Sebbane F, Raoult D, Drancourt M. Emerg Infect Dis. 2010 May;16(5):892-3. doi: 10.3201/eid1605.091280.

  26. Transit through the flea vector induces a pretransmission innate immunity resistance phenotype in Yersinia pestis. Vadyvaloo V, Jarrett C, Sturdevant DE, Sebbane F, Hinnebusch BJ. PLoS Pathog. 2010 Feb 26;6(2):e1000783. doi: 10.1371/journal.ppat.1000783.

  1. Emergence of the Dickeya genus involved duplication of the OmpF porin and the adaptation of the EnvZ-OmpR signaling network. Cochard C, Caby M, Gruau P, Madec E, Marceau M, Macavei I, Lemoine J, Le Danvic C, Bouchart F, Delrue B, Bontemps-Gallo S, Lacroix JM. Microbiol Spectr. 2023 Aug 29;11(5):e0083323. doi: 10.1128/spectrum.00833-23.
  2. Nocardia neocaledoniensis as Rare Cause of Spondylodiscitis. Choquet E, Rodriguez-Nava V, Peltier F, Wankap-Mogo R, Bergeron E, Joseph C, Lemaitre N. Emerg Infect Dis. 2023 Feb;29(2):444-446. doi: 10.3201/eid2902.221389.

  3. Retrospective Multicentric Study on Campylobacter spp. Bacteremia in France: The Campylobacteremia Study. Tinévez C, Velardo F, Ranc AG, Dubois D, Pailhoriès H, Codde C, Join-Lambert O, Gras E, Corvec S, Neuwirth C, Melenotte C, Dorel M, Lagneaux AS, Pichon M, Doat V, Fournier D, Lemaignen A, Bouard L, Patoz P, Hery-Arnaud G, Lemaitre N, Couzigou C, Guillard T, Recalt E, Bille E, Belaroussi Y, Neau D, Cazanave C, Lehours P, Puges M; Campylobacteremia study group. Clin Infect Dis. 2022 Sep 10;75(4):702-709. doi: 10.1093/cid/ciab983.

  4. Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Bachir M, Guglielmetti L, Tunesi S, Billard-Pomares T, Chiesi S, Jaffré J, Langris H, Pourcher V, Schramm F, Lemaître N, Robert J; Isoniazid Resistance Group. J Infect. 2022 Jul;85(1):24-30. doi: 10.1016/j.jinf.2022.05.017.

  5. Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Bonnet I, Haddad E, Guglielmetti L, Bémer P, Bernard L, Bourgoin A, Brault R, Catho G, Caumes E, Escaut L, Fourniols E, Fréchet-Jachym M, Gaudart A, Guillot H, Lafon-Desmurs B, Lanoix JP, Lanotte P, Lemaignen A, Lemaire B, Lemaitre N, Michau C, Morand P, Mougari F, Marigot-Outtandy D, Patrat-Delon S, Perpoint T, Piau C, Pourcher V, Zarrouk V, Zeller V, Veziris N, Jauréguiberry S, Aubry A; CRIOAC Pitié-Salpêtrière and the TB Consilium of the National Reference Center for Mycobacteria. Microorganisms. 2022 Jun 14;10(6):1215. doi: 10.3390/microorganisms10061215.

  6. The arginine deaminase system plays distinct roles in Borrelia burgdorferi and Borrelia hermsii. Richards CL, Raffel SJ, Bontemps-Gallo S, Dulebohn DP, Herbert TC, Gherardini FC. PLoS Pathog. 2022 Mar 14;18(3):e1010370. doi: 10.1371/journal.ppat.1010370. 

  7. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. Bachir M, Guglielmetti L, Tunesi S, Billard-Pomares T, Chiesi S, Jaffré J, Langris H, Pourcher V, Schramm F, Lemaître N, Robert J; Isoniazid Resistance Group. Int J Infect Dis. 2021 Jun;107:86-91. doi: 10.1016/j.ijid.2021.03.093.

  8. A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region. Ngabonziza JCS, Loiseau C, Marceau M, Jouet A, Menardo F, Tzfadia O, Antoine R, Niyigena EB, Mulders W, Fissette K, Diels M, Gaudin C, Duthoy S, Ssengooba W, André E, Kaswa MK, Habimana YM, Brites D, Affolabi D, Mazarati JB, de Jong BC, Rigouts L, Gagneux S, Meehan CJ, Supply P. Nat Commun. 2020 Jun 9;11(1):2917. doi: 10.1038/s41467-020-16626-6.

  9. Prospective evaluation of the Amplidiag® CarbaR+VRE assay for direct screening of carbapenemase producing gram-negative bacilli from rectal swabs. Nadji S, Gaillot O, Hallaert C, Messaadi S, Loukili N, Naas T, Lemaître N. Diagn Microbiol Infect Dis. 2019 Dec;95(4):114890. doi: 10.1016/j.diagmicrobio.2019.114890.

  10. East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide. Li H, Marceau M, Yang T, Liao T, Tang X, Hu R, Xie Y, Tang H, Tay A, Shi Y, Shen Y, Yang T, Pi X, Lamichhane B, Luo Y, Debowski AW, Nilsson HO, Haslam SM, Mulloy B, Dell A, Stubbs KA, Marshall BJ, Benghezal M. PLoS Genet. 2019 Nov 20;15(11):e1008497. doi: 10.1371/journal.pgen.1008497. 

  11. The EnvZ-OmpR Two-Component Signaling System Is Inactivated in a Mutant Devoid of Osmoregulated Periplasmic Glucans in Dickeya dadantii. Caby M, Bontemps-Gallo S, Gruau P, Delrue B, Madec E, Lacroix JM. Front Microbiol. 2018 Oct 30;9:2459. doi: 10.3389/fmicb.2018.02459.

  12. Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation. Levillain F, Poquet Y, Mallet L, Mazères S, Marceau M, Brosch R, Bange FC, Supply P, Magalon A, Neyrolles O. PLoS Pathog. 2017 Nov 27;13(11):e1006752. doi: 10.1371/journal.ppat.1006752. 

  13. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A; CNR MyRMA and the Tuberculosis Consilium of the CNR MyRMA; CNR MyRMA and Tuberculosis Consilium of the CNR MyRMA. Eur Respir J. 2017 Mar 22;49(3):1601719. doi: 10.1183/13993003.01719-2016.

  14. Is a chlorine dioxide wiping procedure suitable for the high-level disinfection of nasendoscopes? Henoun Loukili N, Lemaitre N, Guery B, Gaillot O, Chevalier D, Mortuaire G. J Infect Prev. 2017 Mar;18(2):78-83. doi: 10.1177/1757177416679879. 

  15. Drug design from the cryptic inhibitor envelope. Lee CJ, Liang X, Wu Q, Najeeb J, Zhao J, Gopalaswamy R, Titecat M, Sebbane F, Lemaitre N, Toone EJ, Zhou P. Nat Commun. 2016 Feb 25;7:10638. doi: 10.1038/ncomms10638.

  16. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Pankhurst LJ, Del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fermont JM, Gascoyne-Binzi DM, Kohl TA, Kong C, Lemaitre N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith EG, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook DW; COMPASS-TB Study Group. Lancet Respir Med. 2016 Jan;4(1):49-58. doi: 10.1016/S2213-2600(15)00466-X. 

  17. Disseminated Infection Caused by Francisella philomiragia, France, 2014. Kreitmann L, Terriou L, Launay D, Caspar Y, Courcol R, Maurin M, Lemaître N. Emerg Infect Dis. 2015 Dec;21(12):2260-1. doi: 10.3201/eid2112.150615.

  18. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaître N. PLoS One. 2014 Apr 17;9(4):e95083. doi: 10.1371/journal.pone.0095083. 

  19. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Vuotto F, Berthon C, Lemaitre N, Duhamel A, Balkaran S, Le Ray E, Micol JB, Faure K, Alfandari S. Am J Infect Control. 2013 Jun;41(6):527-30. doi: 10.1016/j.ajic.2012.07.012. 

  20. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, Tap J, Pawlik A, Fiette L, Orgeur M, Fabre M, Parmentier C, Frigui W, Simeone R, Boritsch EC, Debrie AS, Willery E, Walker D, Quail MA, Ma L, Bouchier C, Salvignol G, Sayes F, Cascioferro A, Seemann T, Barbe V, Locht C, Gutierrez MC, Leclerc C, Bentley SD, Stinear TP, Brisse S, Médigue C, Parkhill J, Cruveiller S, Brosch R. Nat Genet. 2013 Feb;45(2):172-9. doi: 10.1038/ng.2517.

  21. Cost-effectiveness of switch to matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine bacterial identification. Gaillot O, Blondiaux N, Loïez C, Wallet F, Lemaître N, Herwegh S, Courcol RJ. J Clin Microbiol. 2011 Dec;49(12):4412. doi: 10.1128/JCM.05429-11.

  22. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaître N. J Clin Microbiol. 2011 May;49(5):1772-6. doi: 10.1128/JCM.02157-10.

  23. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. Van Maele L, Carnoy C, Cayet D, Songhet P, Dumoutier L, Ferrero I, Janot L, Erard F, Bertout J, Leger H, Sebbane F, Benecke A, Renauld JC, Hardt WD, Ryffel B, Sirard JC. J Immunol. 2010 Jul 15;185(2):1177-85. doi: 10.4049/jimmunol.1000115.

  1. Yersinia pestis and Plague: Some Knowns and Unknowns.  Yang R, Atkinson S, Chen Z, Cui Y, Du Z, Han Y, Sebbane F, Slavin P, Song Y, Yan Y, Wu Y, Xu L, Zhang C, Zhang Y, Hinnebusch BJ, Stenseth NC, Motin VL. Zoonoses. 2023 Vol. 3(1) doi: 10.15212/ZOONOSES-2022-0040

  2. What do we know about osmoadaptation of Yersinia pestis?  Bontemps-Gallo S, Lacroix JM, Sebbane F. Arch Microbiol. 2021 Dec 8;204(1):11. doi: 10.1007/s00203-021-02610-1.

  3. Antibiotic Therapy of Plague: A Review.  Sebbane F, Lemaître N. Biomolecules. 2021 May 12;11(5):724. doi: 10.3390/biom11050724.

  4. Yersinia pestis Plasminogen Activator.  Sebbane F, Uversky VN, Anisimov AP. Biomolecules. 2020 Nov 14;10(11):1554. doi: 10.3390/biom10111554.